EMERGENT BIOSOLUTIONS INC. Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2025-10-30: Form 10-Q; Exhibit 10.3; Description Modification No. 14, effective September 9, 2025, to the ACAM2000 Contract..
- 2025-10-30: Form 10-Q; Exhibit 10.2; Description Modification No. 13, effective December 17, 2024, to the ACAM2000 Contract..
- 2025-09-05: Form 8-K; Exhibit 10.1; Description Modification No. 20, effective August 29, 2025 to the BARDA AV7909 Contract..
- 2025-08-07: Form 10-Q; Exhibit 10.1; Description Modification No. 19, effective April 4, 2025, to the BARDA AV7909 Contract..
| Filed | Form | Exhibit | Description |
|---|
| 2025-10-30 | 10-Q | 10.3 | Modification No. 14, effective September 9, 2025, to the ACAM2000 Contract. |
|---|
| 2025-10-30 | 10-Q | 10.2 | Modification No. 13, effective December 17, 2024, to the ACAM2000 Contract. |
|---|
| 2025-09-05 | 8-K | 10.1 | Modification No. 20, effective August 29, 2025 to the BARDA AV7909 Contract. |
|---|
| 2025-08-07 | 10-Q | 10.1 | Modification No. 19, effective April 4, 2025, to the BARDA AV7909 Contract. |
|---|
| 2025-03-04 | 10-K | 10.76 | License Agreement, dated as of December 15, 2014, by and between Opiant Pharmaceuticals, Inc. (formerly known as Lightlake Therapeutics Inc.) and Adapt Pharma Operations Limited. |
|---|
| 2025-03-04 | 10-K | 10.3 | Credit Agreement, dated as of September 30, 2024, by and among Emergent BioSolutions Inc., certain of its subsidiaries, as borrowers, the lenders party thereto from time to time, and Wells Fargo Bank, National Association, as the agent. |
|---|
| 2025-01-08 | 8-K | 10.2 | Modification No. 3, effective December 13, 2024, to the BioThrax IDIQ Contract. |
|---|
| 2025-01-08 | 8-K | 10.1 | Modification No. 18, effective December 12, 2024, to the BARDA AV7909 Contract. |
|---|